LH Laboratory Corp of America Holdings
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
Company profile
Ticker
LH
Exchange
CEO
David P. King
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Quest Diagnostics • RadNet • Guardant Health • Genomic Health • Invitae • Natera • Veracyte • American Shared Hospital Services • Enzo Biochem • CareDx ...
Former names
National Health Laboratories Holdings Inc
SEC CIK
Corporate docs
IRS number
133757370
LH stock data
()
Calendar
8 Aug 19
19 Aug 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 2.88B | 2.79B | 2.79B | 2.83B | |
| Net income | 190.4M | 185.6M | 157.9M | 318.8M | |
| Diluted EPS | 1.93 | 1.86 | 1.56 | 3.1 | |
| Net profit margin | 6.61% | 6.65% | 5.66% | 11.26% | |
| Operating income | 335.7M | 318.2M | 307.7M | 343.4M | |
| Net change in cash | -83.4M | -78M | -465.8M | 671.2M | |
| Cash on hand | 265.4M | 348.8M | 426.8M | 892.6M | |
| Cost of revenue | 2.06B | 2B | 2.02B | 2.04B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 11.33B | 10.31B | 9.55B | 8.68B | |
| Net income | 883.7M | 1.23B | 711.8M | 437.6M | |
| Diluted EPS | 8.61 | 11.81 | 6.82 | 4.35 | |
| Net profit margin | 7.80% | 11.90% | 7.45% | 5.04% | |
| Operating income | 1.33B | 1.31B | 1.27B | 996.8M | |
| Net change in cash | 110.2M | 0 | -399.8M | 136.4M | |
| Cash on hand | 426.8M | 316.6M | 316.6M | 716.4M | |
| Cost of revenue | 8.16B | 7.22B | 6.7B | 5.78B |
Financial data from company earnings reports
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
Additionally, Advisor, AMCA, birth, Booker, Bureau, CEO, certiorari, Chairman, collaborate, Colorado, Committee, confidentiality, Connecticut, constant, conveyed, copy, Cory, CRP, David, debarment, Eighteen, Exhibit, facsimile, flat, floating, foregoing, free, half, hereto, identity, Ignacio, indemnified, Indiana, Jan, JPML, King, learning, mailing, Menendez, MIB, Mitchell, mutually, negligence, notified, oversight, Panel, Pennsylvania, President, repay, Robert, Sacramento, salary, slightly, Social, standstill, stopped, subscriber, text, unauthorized, unsuccessful, user, workforce
Removed:
combined, disbarment, driven, feature, forma, Gonzalez, investee, issuer, longer, Maria, nutritional, participating, pro, reached, reinvested, remove, representation, round, SERP, Specifically, staffing
Financial reports
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
3 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
30 Oct 18
10-Q
2018 Q2
Quarterly report
27 Jul 18
10-Q
2018 Q1
Quarterly report
1 May 18
10-K
2017 FY
Annual report
27 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
2 Aug 17
10-Q
2017 Q1
Quarterly report
28 Apr 17
Current reports
8-K
Regulation FD Disclosure
29 Jul 19
8-K/A
Labcorp Announces 2019 Second Quarter Results
26 Jul 19
8-K
Labcorp Announces 2019 Second Quarter Results
25 Jul 19
8-K
Labcorp Expands Consumer-initiated Test Offering
22 Jul 19
8-K
Regulation FD Disclosure
1 Jul 19
8-K
Regulation FD Disclosure
25 Jun 19
8-K
Regulation FD Disclosure
18 Jun 19
8-K
Labcorp and Qiagen Announce New Therascreen PIK3CA Mutation Analysis Companion Diagnostic for Metastatic Breast Cancer
7 Jun 19
8-K
Labcorp Announces New Leadership Roles
5 Jun 19
8-K
Regulation FD Disclosure
4 Jun 19
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Aug 17
FWP
Free writing prospectus
16 Aug 17
424B5
Prospectus supplement for primary offering
15 Aug 17
S-3ASR
Automatic shelf registration
15 Aug 17
SC TO-T/A
Third party tender offer statement (amended)
7 Sep 16
SC TO-T/A
Third party tender offer statement (amended)
30 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
26 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
23 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
19 Aug 16
SC TO-T/A
Third party tender offer statement (amended)
16 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
29 Mar 19
DEF 14A
Definitive proxy
29 Mar 19
DEFA14A
Additional proxy soliciting materials
6 Apr 18
DEF 14A
Definitive proxy
30 Mar 18
DEFA14A
Additional proxy soliciting materials
30 Mar 18
DEF 14A
Definitive proxy
31 Mar 17
DEFA14A
Additional proxy soliciting materials
31 Mar 17
DEFA14A
Additional proxy soliciting materials
1 Apr 16
DEF 14A
Definitive proxy
1 Apr 16
DEF 14A
Definitive proxy
3 Apr 15
Other
SD
Conflict minerals disclosure
30 May 19
SD
Conflict minerals disclosure
29 May 18
SD
Conflict minerals disclosure
30 May 17
UPLOAD
Letter from SEC
9 May 17
CORRESP
Correspondence with SEC
3 May 17
UPLOAD
Letter from SEC
24 Apr 17
CORRESP
Correspondence with SEC
17 Apr 17
UPLOAD
Letter from SEC
5 Apr 17
SD
Conflict minerals disclosure
27 May 16
SD
Conflict minerals disclosure
29 May 15